(NASDAQ: NGNE) Neurogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Neurogene's earnings in 2025 is -$84,394,000.On average, 5 Wall Street analysts forecast NGNE's earnings for 2025 to be -$69,390,056, with the lowest NGNE earnings forecast at -$80,779,045, and the highest NGNE earnings forecast at -$61,654,677.
In 2026, NGNE is forecast to generate -$80,636,325 in earnings, with the lowest earnings forecast at -$104,327,706 and the highest earnings forecast at -$65,936,252.